Vigil Neuroscience, Inc. (VIGL)
NASDAQ: VIGL · Real-Time Price · USD
1.930
+0.040 (2.12%)
Jan 17, 2025, 4:00 PM EST - Market closed
Vigil Neuroscience Employees
Vigil Neuroscience had 69 employees as of December 31, 2023. The number of employees increased by 13 or 23.21% compared to the previous year.
Employees
69
Change (1Y)
13
Growth (1Y)
23.21%
Revenue / Employee
n/a
Profits / Employee
-$1,197,087
Market Cap
78.81M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 69 | 13 | 23.21% |
| Dec 31, 2022 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
VIGL News
- 12 days ago - Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones - GlobeNewsWire
- 4 months ago - Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - GlobeNewsWire
- 4 months ago - Vigil Neuroscience to Present at Cantor Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Vigil Neuroscience to Present at Upcoming September Investor Conferences - GlobeNewsWire
- 5 months ago - Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease - GlobeNewsWire
- 6 months ago - Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference - GlobeNewsWire
- 6 months ago - Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP - GlobeNewsWire